Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25744948 | 0.83 | TOP2A (0.36) | TOP2ASLC9A1 | |
| SCHEMBL18460627 | 0.83 | NPC1 (0.35) | TOP2APTGS2 | |
| SCHEMBL18460735 | 0.83 | NPC1 (0.35) | TOP2APTGS2 | |
| SCHEMBL24665883 | 0.81 | TOP2A (0.32) | TOP2A | |
| SCHEMBL20711389 | 0.81 | TOP2A (0.39) | TOP2A | |
| SCHEMBL25857817 | 0.80 | TOP2A (0.39) | TOP2ASLC9A1 | |
| SCHEMBL25744939 | 0.78 | — | — | |
| SCHEMBL19303015 | 0.77 | NPC1 (0.32) | — | |
| SCHEMBL24769809 | 0.75 | — | — | |
| SCHEMBL24380279 | 0.75 | KMT2A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11746113-B2 | Labelled cannabinergic ligands and related analogs | MAKRIYANNIS ALEXANDROS (US) | 2023-09-05 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | ARRAY BIOPHARMA INC (US) | 2022-02-15 | — | — | US | disclosed |
| US-11174281-B1 | Modified nucleotides and uses thereof | Singular Genomics Systems, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210316006-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-10-14 | — | — | US | disclosed |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | MAKRIYANNIS ALEXANDROS (US) | 2021-09-30 | — | — | US | disclosed |
| US-20200361980-A1 | 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200306243-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2020-10-01 | — | — | US | disclosed |
| US-RE48175-E1 | Hydrophobically tagged small molecules as inducers of protein degradation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-10392393-B2 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-20190055254-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | TOP2A 2735/4885SLC9A1 3879/4885PTGS2 491/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | TOP2A 2735/4885SLC9A1 3879/4885PTGS2 491/4885 |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | TOP2A 4182/4885SLC9A1 1003/4885PTGS2 1337/4885 |
| US-11746113-B2 | Labelled cannabinergic ligands and related analogs | CNR1, CNR2, CHRND | TOP2A 4395/4885SLC9A1 1564/4885PTGS2 1146/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | TOP2A 4794/4885SLC9A1 378/4885PTGS2 2778/4885 |
| US-20190055254-A1 | PYRROLOBENZODIAZEPINES | HRH3, HRH4, HRH2 | TOP2A 953/4885SLC9A1 2297/4885PTGS2 1244/4885 |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | TOP2A 4815/4885SLC9A1 409/4885PTGS2 2777/4885 |
| US-20200306243-A1 | COMPOUNDS AND CONJUGATES THEREOF | TOP2A, TOP1, TOP2B | TOP2A 1/4885SLC9A1 4426/4885PTGS2 3636/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | TOP2A 2735/4885SLC9A1 3879/4885PTGS2 491/4885 |
| US-20210316006-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | BCR, MCL1, CD79B | TOP2A 50/4885SLC9A1 3023/4885PTGS2 4625/4885 |
| US-11174281-B1 | Modified nucleotides and uses thereof | NUDT1, RNMT, ADAR | TOP2A 623/4885SLC9A1 2987/4885PTGS2 2718/4885 |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | MAP3K1, MAP3K3, MAP3K2 | TOP2A 2719/4885SLC9A1 3877/4885PTGS2 2313/4885 |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | CNR1, CNR2, CHRND | TOP2A 4463/4885SLC9A1 1532/4885PTGS2 1188/4885 |
| US-10392393-B2 | Pyrrolobenzodiazepines | HRH3, HRH4, HRH2 | TOP2A 953/4885SLC9A1 2297/4885PTGS2 1244/4885 |
| US-20200361980-A1 | 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP51A1, KHK, HSD17B7 | TOP2A 1360/4885SLC9A1 4765/4885PTGS2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.